135 related articles for article (PubMed ID: 1376692)
1. Value of biochemical markers in the management of disseminated prostatic cancer.
Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
[TBL] [Abstract][Full Text] [Related]
2. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Cooper EH; Armitage TG; Robinson MR; Newling DW; Richards BR; Smith PH; Denis L; Sylvester R
Cancer; 1990 Sep; 66(5 Suppl):1025-8. PubMed ID: 1697498
[TBL] [Abstract][Full Text] [Related]
3. The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
Emtage LA; Lewis PW; Blackledge GR
Br J Urol; 1987 Dec; 60(6):572-7. PubMed ID: 2447997
[TBL] [Abstract][Full Text] [Related]
4. Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma.
Matzkin H; Soloway MS
Urology; 1992 Jul; 40(1):78-80. PubMed ID: 1377847
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
6. Tumor markers in prostate cancer.
Cooper EH; Robinson MR; Whelan P; Ferro MA
Cancer; 1992 Jul; 70(1 Suppl):225-9. PubMed ID: 1376192
[TBL] [Abstract][Full Text] [Related]
7. [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate].
Petrone U; Gaspari G; Marascia G; Magnocavallo N; Petrone D; Tucci C
Minerva Urol Nefrol; 1990; 42(2):73-5. PubMed ID: 1697431
[TBL] [Abstract][Full Text] [Related]
8. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
Dundas GS; Porter AT; Venner PM
Cancer; 1990 Jul; 66(1):45-8. PubMed ID: 1693877
[TBL] [Abstract][Full Text] [Related]
10. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.
Turkes A; Nott J; Turkes AO; Griffiths K
Am J Clin Oncol; 1988; 11 Suppl 2():S77-9. PubMed ID: 2468280
[TBL] [Abstract][Full Text] [Related]
11. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
Kerle D; Williams G; Ware H; Doble A; Allen J; Bloom SR
Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
[TBL] [Abstract][Full Text] [Related]
12. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
Morote J; de Torres JA
Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
14. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
[TBL] [Abstract][Full Text] [Related]
15. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer.
Matzkin H; Lewyshon O; Ayalon D; Braf Z
Cancer; 1989 Apr; 63(7):1287-91. PubMed ID: 2465816
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen in management of prostatic carcinoma.
Brawer MK; Lange PH
Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer.
Morote J; Ruibal A; Palou J; de Torres JA; Soler-Roselló A
Int J Biol Markers; 1988; 3(1):23-8. PubMed ID: 2470838
[TBL] [Abstract][Full Text] [Related]
18. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up.
Bauer HW
Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908
[TBL] [Abstract][Full Text] [Related]
19. Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study.
Maier U; Simak R
Br J Urol; 1990 May; 65(5):509-12. PubMed ID: 1693867
[TBL] [Abstract][Full Text] [Related]
20. Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex).
Siddall JK; Hetherington JW; Cooper EH; Newling DW; Robinson MR; Richards B; Denis L
Br J Urol; 1986 Dec; 58(6):676-82. PubMed ID: 2432985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
